Metabolic Disorders Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Global Metabolic Disorders Therapeutics Market is segmented By Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy), By Route of Administration (Oral, Parenteral, Others), By Application (Lysosomal Storage diseases, Hypercholesterolemia, Obesity, Diabetes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Metabolic Disorders Therapeutics Market Overview

The Global Metabolic Disorders Therapeutics Market reached USD 68.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 122.3 billion by 2030. The global metabolic disorders therapeutics market is expected to exhibit a CAGR of 7.8% during the forecast period 2023-2030. Metabolic disorders encompass a wide range of medical conditions that involve abnormal chemical reactions and processes in the body's metabolism.

Metabolism refers to the biochemical processes in cells that convert nutrients into energy and other necessary substances. These disorders can impact the breakdown and utilization of carbohydrates, proteins, and fats, as well as the production and regulation of enzymes and hormones. They can be inherited or acquired due to environmental factors, lifestyle choices, or underlying health conditions.

There are numerous types of metabolic disorders, each with its specific characteristics and impact on the body. Some common examples include diabetes, obesity, inherited metabolic disorders, and hypercholesterolemia, among others. Treatment approaches vary depending on the specific disorder but may include dietary modifications, medications, enzyme replacement therapies, and lifestyle changes.

Furthermore, the increasing prevalence of metabolic disorders, growing investment in research and development, and strategic collaborations and partnerships are the factors expected to drive the market growth over the forecast period.

Metabolic Disorders Therapeutics Market Scope

Metabolic Disorders Therapeutics Market Dynamics

The Rising Courses and Workshops For Research in Metabolic Disorders are Expected to Drive Global Metabolic Disorders Therapeutics Market Growth   

According to an EMBO article published in 2022, obesity affects more than 17% of adults in Europe and is a significant contributing factor to the development of type 2 diabetes and other conditions associated with metabolic syndrome. These conditions include elevated blood pressure, high lipid levels, non-alcoholic fatty liver disease, and cardiovascular disease.

The EMBO Workshop, conducted to share the latest research in the field of metabolism, aims to provide insights into adipocyte biology, liver metabolism, and their interaction with the microbiota. 

Additionally, the workshop focuses on understanding how these metabolic alterations can impact heart disease. The workshop specifically emphasizes the importance of organ crosstalk and how signaling in one tissue can affect metabolism in other tissues. The ultimate goal is to uncover novel insights into the underlying causes of these disorders and explore potential avenues for new therapies.

Therefore, by investigating the complex interplay between different tissues, researchers aim to gain valuable insights that may lead to the development of new therapeutic approaches for metabolic disorders and associated conditions like type 2 diabetes and cardiovascular disease. Thus, owing to the above factors, the market is expected to drive over the forecast period.

The Increasing Clinical Trials for Metabolic Disorder Therapies are Expected to Drive Global Metabolic Disorders Therapeutics Market Growth

According to ClinicalTrials.Com, in June 2023, a Phase IV interventional study was conducted by I.R.C.C.S. Fondazione Santa Lucia to assess the clinical efficacy of pharmacological treatments that target energy metabolism, specifically evaluated through gait analysis, on motor function in patients with Parkinson's disease. The study is estimated to be completed by May 2026. 

Likewise, in 2021, the University Medical Centre Ljubljana conducted an interventional study to compare atherogenic risk factors and the effectiveness of nutritional treatment in adult patients with Phenylketonuria. The estimated completion date of the study is September 1, 2026. Hence, owing to the above factors, the market is expected to drive over the forecast period.

Implications for Disease Severity and Individualized Treatment Strategies are Expected to Hamper Global Metabolic Disorders Therapeutics Market Growth

Inborn errors of metabolism (IEMs) encompass a diverse group of genetic disorders that affect various metabolic pathways. Examples include disorders like Gaucher's disease, Tay-Sachs disease, and homocystinuria. The specific genetic mutations and their impact on enzyme function can vary widely among different individuals with these disorders, leading to variations in disease severity and treatment approaches.

Thus, from the above factors, the market is expected to hamper over the forecast period.

For more details on this report –Request for Sample

Metabolic Disorders Therapeutics Market  Segment Analysis

The global metabolic disorders therapeutics market is segmented based on disease type, therapy type, route of administration, and region.

Owing to the Increasing Prevalence of Obesity, Rising Clinical Trials, the Disease Type Segment Accounted for Approximately 28.2% of the Metabolic Disorders Therapeutics Market Share 

According to the World Obesity Federation's World Obesity Atlas 2023, the global economic impact of overweight and obesity is projected to reach D 4.32 trillion annually by 2035 if prevention and treatment measures are not improved. This accounts for almost 3% of the global GDP and is comparable to the impact of COVID-19 in 2020.

The report predicts that by 2035, over half of the global population (51%, or over 4 billion people) will be living with either overweight or obesity if current trends continue. Nearly 2 billion people, or 1 in 4 individuals, will have obesity. The prevalence of childhood obesity is also expected to more than double by 2035, with rates predicted to increase by 100% among boys and 125% among girls.

Notably, lower-income countries are experiencing rapid increases in obesity rates. Among the 10 countries with the greatest expected increases in obesity globally, 9 are from low or lower-middle-income countries in Asia or Africa.

The World Obesity Federation is calling for comprehensive national action plans to address obesity, based on the new recommendations from the World Health Organization. The Atlas report will be presented to UN policymakers, member states, and civil society at a high-level policy event on March 6th. 

Furthermore, in 2022, an interventional study on Multidisciplinary Intervention and Cognitive Remediation Therapy for Adults With Obesity was conducted by Universidad Autonoma de Ciudad Juarez. The study is estimated to be completed by May 2023. 

Therefore, by addressing this growing public health crisis, we can strive to mitigate the economic burden, improve the well-being of individuals, and build a healthier future for generations to come. Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Metabolic Disorders Therapeutics Market Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing FDA approvals, Rising Clinical Trials, and Increasing Investment in the Metabolic Disorder Research 

On November 17, 2022, Provention Bio's teplizumab became the first-ever preventive treatment for type 1 diabetes after receiving approval from the US Food and Drug Administration (FDA).

Similarly, on April 27, 2023, Eli Lilly and Company presented new data that strengthens its efforts to obtain expedited approval for a new treatment. The topline findings from a study called SURMOUNT-2 demonstrate significant weight loss, up to 15.7%, in individuals with both Type 2 diabetes and obesity. With these promising results, the company now possesses all the necessary information to finalize its submission to the FDA, aiming for potential approval before the year's end.

Also, in January 2023, prominent figures such as Elon Musk and Michael Rubin expressed their support for GLP-1 drugs like Wegovy and Ozempic due to their effectiveness in weight loss. Although these medications are primarily associated with treating obesity and diabetes, they have now become significant in the field of weight loss medicine. 

However, their growing popularity has also led to concerns regarding a nationwide shortage. To address this, online health company Ro is introducing a weight management program that includes the direct shipment of GLP-1 drugs to patients' homes. The program also incorporates real-time tracking of patients' progress toward achieving the clinical target of a 15% reduction in body weight within a year. 

Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Source: DataM Intelligence Analysis (2023)

Metabolic Disorders Therapeutics Market Players

The major global players in the market include Sanofi S.A, Merck KgaA, Amgen, Inc, AstraZeneca PLC, Actelion Pharmaceuticals Ltd, Eli Lilly and Company, Shire PLC, Cipla, Inc, Inc., CymaBay Therapeutics, Inc, and Boehringer Ingelheim GmbH among others.

COVID-19 Impact on Metabolic Disorders Therapeutics Market 

Russia Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine has had a significant impact on various aspects of both countries' healthcare systems, including the metabolic disorders therapeutics market.

The war has led to disruptions in healthcare services, including difficulties in accessing medications, healthcare facilities, and specialized treatments for metabolic disorders. The displacement of populations and the destruction of healthcare infrastructure have further compounded these challenges.

In addition, economic instability caused by the conflict can affect the affordability and availability of medications and healthcare services. The allocation of limited resources towards the war efforts may result in reduced investment in healthcare and research for metabolic disorders.

The war-induced stress, displacement, and trauma experienced by individuals affected by the conflict can also have indirect effects on metabolic disorders. Stress and psychological factors can impact the management and control of metabolic disorders, potentially exacerbating symptoms and leading to complications.

By Disease Type

• Lysosomal Storage Diseases
  • Gaucher’s Disease
  • Metachromatic Leukodystrophy
  • Hurler - Scheie
  • Sanfilipo A
  • Others
• Diabetes
• Obesity
• Inherited Metabolic Disorders
• Hypercholesterolemia
• Others 

By Therapy Type

• Enzyme Replacement Therapy
• Cellular Transplantation
• Small Molecule Based Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy

By Route of Administration

• Oral
• Parenteral
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On May 18, 2022, Sun Pharma announced to introduce a medication aimed at lowering low-density lipoprotein (LDL) cholesterol levels. The Indian pharmaceutical company's subsidiary is planning to launch Bempedoic Acid, an innovative oral drug that is the first of its kind, in India. The drug will be marketed under the brand name Brillo.
• On March 22, 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) extended the approval of Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). 

Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for children as young as 5 years old to control dangerously high levels of low-density lipoprotein cholesterol (LDL-C) caused by HoFH. Evkeeza was initially approved as an adjunct to other lipid-lowering therapies in those aged 12 years and older with HoFH in February 2021.

• On March 1, 2023, Amgen announced new Repatha (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, a siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%. 

Additional data from Amgen's Center for Observational Research and Amgen-funded investigator studies, including YELLOW-III from Mount Sinai will be presented at the American College of Cardiology's 72nd Annual Scientific Session together with World Heart Federation's World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA, March 4-6, 2023.

Why Purchase the Report?

• To visualize the global metabolic disorders therapeutics market segmentation based on the disease type, therapy type, route of administration, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of metabolic disorders therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global metabolic disorders therapeutics market report would provide approximately 62 tables, 63 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceuticals related reports, please click here